title: Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database.
abstract: OBJECTIVE
  To test the hypothesis whether the effects of GH replacement therapy in adults could be affected by prior pituitary irradiation, the baseline characteristics and response to GH were evaluated in adults with severe GH deficiency (GHD), who had received or not irradiation for the treatment of pituitary adenoma or craniopharyngioma.
  
  
  METHODS
  Data from 447 patients, who had received radiotherapy (427 in addition to surgery), and 630 patients, who were operated on but not irradiated for their tumour, were retrieved from Pfizer International Metabolic Database (KIMS) and compared at baseline and 1 and 2 years following the onset of GH replacement.
  
  
  RESULTS
  Irradiated and non-irradiated patients exhibited the expected phenotype of GHD at baseline. However, irradiated patients had a greater impairment in the quality of life (QoL), a higher fat mass, lower high-density lipoprotein cholesterol levels and a lower bone mineral content (BMC) than non-irradiated patients. Treatment with GH induced similar changes in both groups. After 1 year of GH replacement, there was an increase in serum IGF-I and fat-free mass, a reduction in fat mass and an improvement in QoL, all changes being equivalent in irradiated and non-irradiated patients. The lipid profile also improved with the irradiated patients showing a better response. These beneficial effects were maintained and the BMC also increased in both groups by the second year of treatment.
  
  
  CONCLUSIONS
  This analysis shows that prior irradiation for pituitary adenoma or craniopharyngioma does not compromise the beneficial effects of GH replacement therapy.
authors.affiliation: UCL St Luc Hospital, B-1200 Brussels, and University Hospital, Antwerp, B-2650 Edegem, Belgium. maiter@diab.ucl.ac.be
authors.forename: D
authors.initials: D
authors.lastname: Maiter
authors.forename: R
authors.initials: R
authors.lastname: Abs
authors.forename: G
authors.initials: G
authors.lastname: Johannsson
authors.forename: M
authors.initials: M
authors.lastname: Scanlon
authors.forename: P J
authors.initials: PJ
authors.lastname: Jönsson
authors.forename: P
authors.initials: P
authors.lastname: Wilton
authors.forename: M
authors.initials: M
authors.lastname: Koltowska-Häggström
mesh_terms: D000236:Adenoma / Q000532:radiotherapy*; D000328:Adult; D003397:Craniopharyngioma / Q000532:radiotherapy*; D016208:Databases, Factual; D005260:Female; D005500:Follow-Up Studies; D019382:Human Growth Hormone / Q000008:administration & dosage* / Q000172:deficiency; D006801:Humans; D007018:Hypopituitarism / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000532:radiotherapy*; D011878:Radiotherapy / Q000009:adverse effects*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D019382:Human Growth Hormone